Dr. David O'Malley, MD – Hilliard, OH

  • Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...  

    David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology
  • You Might Also Like